The Europe NGS Market is expected to grow at a CAGR of 14.8% from 2023 to 2030 to reach $6.40 billion by 2030. The field of genomics has surpassed expectations over the past three decades due to massive changes in technology that allowed researchers to interrogate larger pieces of the human genome. Next-generation Sequencing (NGS) is one such massively parallel or deep sequencing technology that helps identify the sequence of nucleotides in DNA/RNA. Due to its high-throughput production, efficient instrument run, and lower cost compared to the traditional Sanger first-generation sequencing method, NGS is highly preferred for large-scale genomic and transcriptomic sequencing.
The growth of this market is driven by factors such as the rising cancer prevalence and increasing application of NGS in cancer treatment and research, the declining costs of genome sequencing, technological advancements in sequencing, and increasing pharmaceutical R&D expenditures. However, the high costs of NGS systems and consumables and the availability of alternative technologies restrain the market's growth.
Additionally, the increasing applications of NGS, the rising adoption of bioinformatics and genomic data management solutions, and government initiatives supporting large-scale genomic sequencing projects are expected to offer significant market growth opportunities. However, the lack of skilled professionals and regulatory and standardization concerns in diagnostic testing pose a significant challenge to the market's growth.
The prevalence of cancer is rising across the world. According to GLOBOCAN, in 2020, 4.4 million people were diagnosed with cancer in Europe. This number is expected to rise to 4.9 million by 2030. The most common types of cancer are lung cancer, breast cancer, colon cancer, prostate cancer, and rectum cancer. The utilization of NGS is growing in cancer treatment and research. NGS has been proven as an effective method for gaining a more precise and comprehensive understanding of the molecular foundations of individual cancers.
Targeted medicines are quickly becoming the new standard of care for cancer. Also, NGS is currently starting to be used in clinical oncology to improve cancer therapy through a variety of techniques, including the discovery of novel and rare cancer mutations, the identification of cancer mutation carriers, and the development of specialized therapeutic approaches known as personalized medicine (PM). Further, NGS has the additional advantage of offering an expanded view of the disease landscape and revealing cancer development pathways. Thus, the rising cancer prevalence and increasing application of NGS in cancer treatment drive the demand for NGS in Europe.
Click here to: Get Free Sample Pages of this Report
The Increasing Applications of NGS Create an Opportunity for the Market
NGS has gained much significance in clinical practices for oncology, reproductive health, Mendelian disorders, complex diseases, and infectious diseases. In the coming years, NGS is expected to diversify in other clinical areas, with a considerable reduction in sequencing costs. The technology is expected to show substantial penetration in applications such as liquid biopsies for the early detection and monitoring of cancer and reproductive health applications. New biomarkers and actionable mutations are being identified by researchers. For instance, in February 2023, Dxcover Limited (U.K.) raised USD 11.9 million in funding to support the development of a liquid biopsy technology platform for the diagnosis of early-stage cancers, which includes colorectal and brain cancers. NGS-based liquid biopsy analysis finds a small quantity of remaining tumor DNA or RNA in post-treatment samples, which enables responses to treatment monitoring and early disease detection, creating growth opportunities for the players operating in the NGS market.
Consumables Segment to Account for the Largest Share of the Market in 2023
Among the offerings, in 2023, the consumables segment is expected to account for the largest share of the Europe NGS market. The recurring use of consumables and advancements in target enrichment protocols and associated consumables. Many companies are focusing on partnerships to enhance their consumable offerings. For instance, in February 2022, QIAGEN N.V. (Netherlands) partnered with Element Biosciences, Inc. (U.S.) to validate a selection of its NGS library prep and target enrichment offerings on the latter’s AVITI System.
Targeted Genome Sequencing Segment to Account for the Largest Share of the Market in 2023
Among sequencing types, in 2023, the targeted genome sequencing segment is expected to account for the largest share of the Europe NGS market. The large share of this segment is attributed to low sequencing costs as compared to other sequencing technologies, higher sensitivity of the technique to call variants, and advancements in targeted genome sequencing technologies. Advancements in targeted genome sequencing have improved the diagnosis of monogenic intestinal and pediatric disorders. In addition to disease diagnosis, this technology has enabled researchers to study gene-drug associations, which has helped researchers design gene-specific drugs with high specificity.
Sequencing by Synthesis Segment to Account for the Largest Share of the Market in 2023
Among the technologies, in 2023, the sequencing by synthesis segment is expected to account for the largest share of the Europe NGS market. The key factors supporting the large market share of this segment are low sequencing costs compared to other sequencing technologies such as ion semiconductor sequencing, nanopore sequencing, and many others, higher sensitivity of the technique to call variants, and proven results in identifying primary immunodeficiencies and specific gene-associated diseases.
Research and Other Applications Segment to Account for the Largest Share of the Market in 2023
Among the applications, in 2023, the research and other applications segment is expected to account for the largest share of the Europe NGS market. The increasing adoption of sequencing-based tests in laboratories, the growing demand for personalized medicines, the increasing NGS-based research, and the growing prevalence of genetic disorders. For instance, according to the data published by the German Center for Lung Research in July 2023, in Germany, approximately 2,500 newborns were affected with cystic fibrosis in 2022.
Pharmaceutical & Biotechnology Companies Segment to Account for the Largest Share of the Europe NGS Market in 2023
Among the end users, in 2023, the pharmaceutical & biotechnology segment is expected to account for the largest share of the Europe NGS market. The large market share of this segment is attributed to factors such as the increasing adoption of advanced technologies for research purposes and increasing research for drug discovery with widening NGS applications, rising incidence of chronic diseases, and increasing R&D spending by pharmaceutical & biotechnology companies. For instance, according to the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) data, in 2020, global pharmaceutical R&D spending was USD 189 billion, which is expected to increase up to USD 202 million by 2024. NGS enables pharmaceutical & biotechnology companies to identify and validate biomarkers that can be used in developing new diagnostic tests and therapies, which drives the adoption of NGS among pharmaceutical & biotechnology companies.
Germany to Account for the Largest Market Share in 2023
In 2023, Germany is expected to account for the largest share of the Europe NGS market. The large share is primarily attributed to the increasing number of sequencing projects, growing research for the development of personalized medicine in the country, the establishment of new healthcare facilities and modernizing existing ones, the large pool of patients with gene-associated disorders, growing research activities for developing personalized medicines, and the rising prevalence of cancer. For instance, according to GLOBOCAN, 19.3 million people were diagnosed with cancer in 2020. This number is expected to rise to 24.6 million by 2030. NGS has helped to make it easy for researchers to identify and clarify hundreds of genes linked to cancer; these discoveries are certain to contribute to the identification of new therapeutic targets.
Key Players
The report includes a competitive landscape based on an extensive assessment of the key strategic developments that led market participants to adopt over the past three years 2020–2023. The key players profiled in the Europe NGS market report are Thermo Fisher Scientific Inc. (U.S.), Illumina, Inc. (U.S.), Qiagen N.V. (Netherlands), F. Hoffmann-La Roche Ltd (Switzerland), PerkinElmer, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Pacific Biosciences of California Inc. (U.S.), Danaher Corporation (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Oxford Nanopore Technologies Plc. (U.K.), and 10X Genomics, Inc. (U.S.).
Scope of the Report:
Europe NGS Market Assessment, by Offering
Europe NGS Market Assessment, by Sequencing Type
Europe NGS Market Assessment, by Technology
Europe NGS Market Assessment, by Application
Europe NGS Market Assessment, by End User
Europe NGS Market Assessment, by Geography
Key questions answered in the report:
This study offers a detailed assessment of the Europe NGS market, including the market size & forecast for various segmentations like offering, sequencing type, technology, application, and end user. This report also involves the value analysis of various segments and sub-segments of NGS at the country level.
The Europe NGS market is projected to reach $6.40 billion by 2030, at a CAGR of 14.8% during the forecast period.
Among the offerings, in 2023, the consumables segment is expected to account for the largest share of the Europe NGS market. The large market share of this segment is attributed to the recurring use of consumables, rising demand for NGS-based diagnostic tests, and increasing applications of NGS in oncology, reproductive health diagnosis, and drug discovery is increasing the demand for consumables.
In 2023, the targeted genome sequencing segment is expected to account for the largest share of the Europe NGS market. The large market share of this segment is attributed to the highly accurate results, increasing demand for targeted genome sequencing, and low cost with high reliability.
The growth of this market is driven by factors such as the rising cancer prevalence and increasing application of NGS in cancer treatment and research, the declining costs of genome sequencing, technological advancements in sequencing procedures, and increasing pharmaceutical R&D expenditures. Additionally, the increasing applications of NGS, the rising adoption of bioinformatics and genomic data management solutions, and government initiatives supporting large-scale genomic sequencing projects are expected to offer significant market growth opportunities.
The key players profiled in the Europe NGS market report are Thermo Fisher Scientific Inc. (U.S.), Illumina, Inc. (U.S.), Qiagen N.V. (Netherlands), F. Hoffmann-La Roche Ltd (Switzerland), PerkinElmer, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Pacific Biosciences of California Inc. (U.S.), Danaher Corporation (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Oxford Nanopore Technologies Plc. (U.K.), and 10X Genomics, Inc. (U.S.).
This report provides pre & post COVID-19 market estimates.
1. Introduction
1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency & Limitations
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Approach
2.2. Process of Data Collection and Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders from the Industry
2.3. Market Sizing and Forecasting
2.3.1. Market Size Estimation Approach
2.3.2. Growth Forecast Approach
2.4. Assumptions for the Study
3. Executive Summary
4. Market Insights
4.1. Overview
4.2. Drivers
4.2.1. Technological Advancements in Sequencing
4.2.2. The Declining Costs of Genome Sequencing
4.2.3. Rising Cancer Prevalence and Increasing Application of NGS in Cancer Treatment and Research
4.2.4. Increasing Pharmaceutical R&D Expenditures
4.3. Restraints
4.3.1. High Costs of NGS Systems and Consumables
4.3.2. Availability of Alternative Technologies
4.4. Opportunities
4.4.1. Government Initiatives Supporting Large-scale Genomic Sequencing Projects
4.4.2. Rising Adoption of Bioinformatics and Genomic Data Management Solutions
4.4.3. Increasing Applications of NGS
4.5. Challenges
4.5.1. Lack of Skilled Professionals
4.5.2. Regulatory and Standardization Concerns in Diagnostic Testing
4.6. Factor Analysis
4.7. Pricing Analysis
4.8. Regulatory Analysis
4.9. Porter’s Five Forces Analysis
5. Europe NGS Market Assessment—by Offering
5.1. Overview
5.2. Consumables
5.2.1. Sample Preparation Consumables
5.2.1.1. DNA Extraction and Amplification
5.2.1.2. Library Preparation & Target Enrichment
5.2.1.3. Quality Control
5.2.2. Other Consumables
5.3. NGS Platforms/Instruments
5.4. Software
5.5. Services
6. Europe NGS Market Assessment—by Sequencing Type
6.1. Overview
6.2. Targeted Genome Sequencing
6.3. Whole Genome Sequencing
6.4. Whole Exome Sequencing
6.5. Other Sequencing Types
7. Europe NGS Market Assessment—by Technology
7.1. Overview
7.2. Sequencing by Synthesis
7.3. Ion Semiconductor Sequencing
7.4. Single-molecule Real-time Sequencing (SMRT)
7.5. Nanopore Sequencing
7.6. DNA nanoball sequencing
8. Europe NGS Market Assessment—by Application
8.1. Overview
8.2. Research and Other Applications
8.2.1. Drug Discovery
8.2.2. Agriculture & Animal Research
8.2.3. Other Research Applications
8.3. Clinical Applications
8.3.1. Reproductive Health Diagnosis
8.3.2. Oncology
8.3.3. Infectious Diseases
8.3.4. Other Clinical Applications
9. Europe NGS Market Assessment—by End User
9.1. Overview
9.2. Pharmaceutical & Biotechnology Companies
9.3. Hospitals and Diagnostic Laboratories
9.4. Academic Institutes and Research Centers
9.5. Other End Users
10. Europe NGS Market Assessment—by Country
10.1. Overview
10.2. Germany
10.3. France
10.4. U.K.
10.5. Italy
10.6. Spain
10.7. Switzerland
10.8. Rest of Europe
11. Competition Analysis
11.1. Overview
11.2. Key Growth Strategies
11.3. Competitive Benchmarking
11.4. Competitive Dashboard
11.4.1. Industry Leaders
11.4.2. Market Differentiators
11.4.3. Vanguards
11.4.4. Emerging Companies
11.5. Market Share Analysis/Market Rankings, By Key Players (2022)
12. Company Profiles (Business Overview, Financial Overview, Product Portfolio, and Strategic Developments)
12.1. Thermo Fisher Scientific Inc.
12.2. Illumina, Inc.
12.3. Qiagen N.V.
12.4. F. Hoffmann-La Roche Ltd.
12.5. PerkinElmer, Inc.
12.6. Agilent Technologies, Inc.
12.7. Pacific Biosciences of California Inc.
12.8. Danaher Corporation
12.9. Bio-Rad Laboratories, Inc.
12.10. Oxford Nanopore Technologies Plc.
12.11. 10X Genomics, Inc.
(Note: SWOT Analysis of the Top 5 Companies Will Be Provided)
13. Appendix
13.1. Available Customization
13.2. Related Reports
List of Tables
Table 1 Europe NGS Market, by Offering, 2021–2030 (USD Million)
Table 2 Europe NGS Consumables Market by Type, 2021–2030 (USD Million)
Table 3 Europe NGS Consumables Market by, Country/Region, 2021–2030 (USD Million)
Table 4 Europe NGS Sample Preparation Consumables Market by Type, 2021–2030 (USD Million)
Table 5 Europe NGS Sample Preparation Consumables Market by Country/Region, 2021–2030 (USD Million)
Table 6 Europe NGS DNA Extraction and Amplification Market by Country/Region, 2021–2030 (USD Million)
Table 7 Europe NGS Library Preparation & Target Enrichment Market by Country/Region, 2021–2030 (USD Million)
Table 8 Europe NGS Quality Control Market by Country/Region, 2021–2030 (USD Million)
Table 9 Europe NGS Other Consumables Market by Country/Region, 2021–2030 (USD Million)
Table 10 Europe NGS Platforms/Instruments Market by Country/Region, 2021–2030 (USD Million)
Table 11 Europe NGS Software Market by Country/Region, 2021–2030 (USD Million)
Table 12 Europe NGS Services Market by Country/Region, 2021–2030 (USD Million)
Table 13 Europe NGS Market, by Sequencing Type, 2021–2030 (USD Million)
Table 14 Europe NGS Market for Targeted Genome Sequencing, by Country/Region, 2021–2030 (USD Million)
Table 15 Europe NGS Market for Whole Genome Sequencing, by Country/Region, 2021–2030 (USD Million)
Table 16 Europe NGS Market for Whole Exome Sequencing, by Country/Region, 2021–2030 (USD Million)
Table 17 Europe NGS Market for Other Sequencing Types, by Country/Region, 2021–2030 (USD Million)
Table 18 Europe NGS Market, by Technology, 2021–2030 (USD Million)
Table 19 Europe NGS Market for Sequencing by Synthesis, by Country/Region, 2021–2030 (USD Million)
Table 20 Europe NGS Market for Ion Semiconductor Sequencing, by Country/Region, 2021–2030 (USD Million)
Table 21 Europe NGS Market for Single-molecule Real-time Sequencing (SMRT), by Country/Region, 2021–2030 (USD Million)
Table 22 Europe NGS Market for Nanopore Sequencing, by Country/Region, 2021–2030 (USD Million)
Table 23 Europe NGS Market for DNA nanoball sequencing, by Country/Region, 2021–2030 (USD Million)
Table 24 Europe NGS Market, by Application, 2021–2030 (USD Million)
Table 25 Europe NGS Market for Research and Other Applications, by Type, 2021–2030 (USD Million)
Table 26 Europe NGS Market for Research and Other Applications, by Country/Region, 2021–2030 (USD Million)
Table 27 Europe NGS Market for Drug Discovery, by Country/Region, 2021–2030 (USD Million)
Table 28 Europe NGS Market for Agriculture & Animal Research, by Country/Region, 2021–2030 (USD Million)
Table 29 Europe NGS Market for Other Research Applications, by Country/Region, 2021–2030 (USD Million)
Table 30 Europe NGS Market for Clinical Applications, by Type, 2021–2030 (USD Million)
Table 31 Europe NGS Market for Reproductive Health Diagnosis, by Country/Region, 2021–2030 (USD Million)
Table 32 Europe NGS Market for Oncology, by Country/Region, 2021–2030 (USD Million)
Table 33 Europe NGS Market for Infectious Diseases, by Country/Region, 2021–2030 (USD Million)
Table 34 Europe NGS Market for Other Clinical Applications, by Country/Region, 2021–2030 (USD Million)
Table 35 Europe: NGS Market, by End User, 2021–2030 (USD Million)
Table 36 Europe NGS Market for Hospitals and Diagnostic Laboratories, by Country/Region, 2021–2030 (USD Million)
Table 37 Europe NGS Market for Pharmaceutical & Biotechnology Companies, by Country/Region, 2021–2030 (USD Million)
Table 38 Europe NGS Market for Academic Institutes & Research Centers, by Country/Region, 2021–2030 (USD Million)
Table 39 Europe NGS Market for Other End Users, by Country/Region, 2021–2030 (USD Million)
Table 40 Europe: NGS Market, by Country/Region, 2021–2030 (USD Million)
Table 41 Germany: NGS Market, by Offering, 2021–2030 (USD Million)
Table 42 Germany: NGS Consumables Market by Type, 2021–2030 (USD Million)
Table 43 Germany: NGS Sample Preparation Consumables Market by Type, 2021–2030 (USD Million)
Table 44 Germany: NGS Market, by Sequencing Type, 2021–2030 (USD Million)
Table 45 Germany: NGS Market, by Technology, 2021–2030 (USD Million)
Table 46 Germany: NGS Market, by Application, 2021–2030 (USD Million)
Table 47 Germany: NGS Market for Clinical Applications, by Type, 2021–2030 (USD Million)
Table 48 Germany: NGS Market for Research Applications, by Type, 2021–2030 (USD Million)
Table 49 Germany: NGS Market, by End User, 2021–2030 (USD Million)
Table 50 France: NGS Market, by Offering, 2021–2030 (USD Million)
Table 51 France: NGS Consumables Market by Type, 2021–2030 (USD Million)
Table 52 France: NGS Sample Preparation Consumables Market by Type, 2021–2030 (USD Million)
Table 53 France: NGS Market, by Sequencing Type, 2021–2030 (USD Million)
Table 54 France: NGS Market, by Technology, 2021–2030 (USD Million)
Table 55 France: NGS Market, by Application, 2021–2030 (USD Million)
Table 56 France: NGS Market for Clinical Applications, by Type, 2021–2030 (USD Million)
Table 57 France: NGS Market for Research Applications, by Type, 2021–2030 (USD Million)
Table 58 France: NGS Market, by End User, 2021–2030 (USD Million)
Table 59 U.K.: NGS Market, by Offering, 2021–2030 (USD Million)
Table 60 U.K.: NGS Consumables Market by Type, 2021–2030 (USD Million)
Table 61 U.K.: NGS Sample Preparation Consumables Market by Type, 2021–2030 (USD Million)
Table 62 U.K.: NGS Market, by Sequencing Type, 2021–2030 (USD Million)
Table 63 U.K.: NGS Market, by Technology, 2021–2030 (USD Million)
Table 64 U.K.: NGS Market, by Application, 2021–2030 (USD Million)
Table 65 U.K.: NGS Market for Clinical Applications, by Type, 2021–2030 (USD Million)
Table 66 U.K.: NGS Market for Research Applications, by Type, 2021–2030 (USD Million)
Table 67 U.K.: NGS Market, by End User, 2021–2030 (USD Million)
Table 68 Italy: NGS Consumables Market by Type, 2021–2030 (USD Million)
Table 69 Italy: NGS Sample Preparation Consumables Market by Type, 2021–2030 (USD Million)
Table 70 Italy: NGS Market, by Sequencing Type, 2021–2030 (USD Million)
Table 71 Italy: NGS Market, by Technology, 2021–2030 (USD Million)
Table 72 Italy: NGS Market, by Application, 2021–2030 (USD Million)
Table 73 Italy: NGS Market for Clinical Applications, by Type, 2021–2030 (USD Million)
Table 74 Italy: NGS Market for Research Applications, by Type, 2021–2030 (USD Million)
Table 75 Italy: NGS Market, by End User, 2021–2030 (USD Million)
Table 76 Spain: NGS Market, by Offering, 2021–2030 (USD Million)
Table 77 Spain: NGS Consumables Market by Type, 2021–2030 (USD Million)
Table 78 Spain: NGS Sample Preparation Consumables Market by Type, 2021–2030 (USD Million)
Table 79 Spain: NGS Market, by Sequencing Type, 2021–2030 (USD Million)
Table 80 Spain: NGS Market, by Technology, 2021–2030 (USD Million)
Table 81 Spain: NGS Market, by Application, 2021–2030 (USD Million)
Table 82 Spain: NGS Market for Clinical Applications, by Type, 2021–2030 (USD Million)
Table 83 Spain: NGS Market for Research Applications, by Type, 2021–2030 (USD Million)
Table 84 Spain: NGS Market, by End User, 2021–2030 (USD Million)
Table 85 Switzerland: NGS Market, by Offering, 2021–2030 (USD Million)
Table 86 Switzerland: NGS Consumables Market by Type, 2021–2030 (USD Million)
Table 87 Switzerland: NGS Sample Preparation Consumables Market by Type, 2021–2030 (USD Million)
Table 88 Switzerland: NGS Market, by Sequencing Type, 2021–2030 (USD Million)
Table 89 Switzerland: NGS Market, by Technology, 2021–2030 (USD Million)
Table 90 Switzerland: NGS Market, by Application, 2021–2030 (USD Million)
Table 91 Switzerland: NGS Market for Clinical Applications, by Type, 2021–2030 (USD Million)
Table 92 Switzerland: NGS Market for Research Applications, by Type, 2021–2030 (USD Million)
Table 93 Switzerland: NGS Market, by End User, 2021–2030 (USD Million)
Table 94 Rest of Europe: NGS Market, by Offering, 2021–2030 (USD Million)
Table 95 Rest of Europe: NGS Consumables Market by Type, 2021–2030 (USD Million)Table 66
Table 96 Rest of Europe: NGS Sample Preparation Consumables Market by Type, 2021–2030 (USD Million)
Table 97 Rest of Europe: NGS Market, by Sequencing Type, 2021–2030 (USD Million)
Table 98 Rest of Europe: NGS Market, by Technology, 2021–2030 (USD Million)
Table 99 Rest of Europe: NGS Market, by Application, 2021–2030 (USD Million)
Table 100 Rest of Europe: NGS Market for Clinical Applications, by Type, 2021–2030 (USD Million)
Table 101 Rest of Europe: NGS Market for Research Applications, by Type, 2021–2030 (USD Million)
Table 102 Rest of Europe: NGS Market, by End User, 2021–2030 (USD Million)
Table 103 Recent Developments, by Company, 2020–2023
List of Figures
Figure 1 Research Process
Figure 2 Key Secondary Sources
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply-side & Demand-side)
Figure 6 Market Size Estimation
Figure 7 Europe NGS Market, by Offering, 2023–2030 (USD Million)
Figure 8 Europe NGS Market, by Sequencing Type, 2023–2030 (USD Million)
Figure 9 Europe NGS Market, by Technology, 2023–2030 (USD Million)
Figure 10 Europe NGS Market, by Application, 2023–2030 (USD Million)
Figure 11 Europe NGS Market, by End User, 2023–2030 (USD Million)
Figure 12 Europe NGS Market, by Country/Region
Figure 13 Impact Analysis: Europe NGS Market
Figure 14 Europe NGS Market, by Offering, 2023–2030 (USD Million)
Figure 15 Europe NGS Market, by Sequencing Type, 2023–2030 (USD Million)
Figure 16 Europe NGS Market, by Technology, 2023–2030 (USD Million)
Figure 17 Europe NGS Market, by Application, 2023–2030 (USD Million)
Figure 18 Europe NGS Market, by End User, 2023–2030 (USD Million)
Figure 19 Europe NGS Market, by Country/Region, 2023–2030 (USD Million)
Figure 20 Europe NGS Market Snapshot
Figure 21 Key Growth Strategies Adopted by Leading Players (2020–2023)
Figure 22 Europe NGS Market: Vendor Dashboard
Figure 23 Europe NGS Market: Competitive Benchmarking, by Offering
Figure 24 Europe NGS Market: Competitive Benchmarking, by Sequencing Type
Figure 25 Market Share Analysis: Europe NGS Market (2022)
Figure 26 Thermo Fisher Scientific, Inc.: Financial Snapshot, 2022
Figure 27 Illumina, Inc.: Financial Snapshot, 2022
Figure 28 Qiagen N.V.: Financial Snapshot, 2022
Figure 29 F. Hoffmann-La Roche Ltd: Financial Snapshot, 2022
Figure 30 PerkinElmer, Inc.: Financial Snapshot, 2022
Figure 31 Agilent Technologies, Inc.: Financial Snapshot, 2022
Figure 32 Pacific Biosciences of California, Inc.: Financial Snapshot, 2022
Figure 33 Danaher Corporation: Financial Snapshot, 2022
Figure 34 Oxford Nanopore Technologies Plc.: Financial Snapshot, 2022
Figure 35 10X Genomics, Inc.: Financial Snapshot, 2022
This report provides pre & post COVID-19 market estimates.
This report provides pre & post COVID-19 market estimates.
Published Date: Feb-2024
Published Date: Feb-2024
Published Date: Sep-2023
Published Date: Aug-2023
